Literature DB >> 8013939

Reduced growth hormone secretion in Turner syndrome: is body weight a key factor?

S Cianfarani1, F Vaccaro, A M Pasquino, S A Marchione, F Passeri, G L Spadoni, S Bernardini, A Spagnoli, B Boscherini.   

Abstract

The age-related decline in spontaneous growth hormone (GH) secretion has been suggested to cause growth failure in girls with Turner syndrome (TS). We studied 23 girls (mean age +/- SD: 11.1 +/- 2.7 years) diagnosed to have TS by karyotype analysis. The control group consisted of 18 prepubertal age-matched subjects (10.7 +/- 2.5 years) with growth retardation due to familial short stature and/or constitutional growth delay. In addition, 18 children (10.9 +/- 3.3 years) diagnosed to have GH deficiency by two different provocative tests were chosen as a further comparison group. Spontaneous 12-hour nocturnal GH secretion was assessed by RIA at 30-min intervals. Plasma insulin-like growth factor 1 (IGF-1) levels were determined by RIA after acid-ethanol extraction. Girls with TS had a percentage of ideal body weight significantly higher than controls (p < 0.0001) and showed spontaneous GH secretion significantly lower than controls (mean +/- SD: 3.2 +/- 1.6 in TS vs. 5.5 +/- 1.3 microgram/l in controls; p < 0.0001) but higher than GH-deficient patients (1.3 +/- 0.8 microgram/l; p < 0.0001). No significant difference was found in IGF-1 levels between TS patients and controls, whereas GH-deficient children showed IGF-1 levels significantly lower than those of TS patients (p < 0.0005). As expected, GH concentrations correlated with bone age in controls (r = 0.51, p < 0.05), whereas no relationship was seen in TS. interestingly, in TS, GH levels were negatively related to the percentage of ideal body weight (r = -0.43, p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013939     DOI: 10.1159/000183873

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  3 in total

1.  Plasma GH responses to GHRH, arginine, L-dopa, pyridostigmine, sequential administrations of GHRH and combined administration of PD and GHRH in Turner's syndrome.

Authors:  K Hanew; A Tanaka; A Utsumi
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

2.  Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome.

Authors:  Nicole Wooten; Vladimir K Bakalov; Suvimol Hill; Carolyn A Bondy
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

3.  Prevalence of Celiac Disease in Patients With Turner Syndrome: Systematic Review and Meta-Analysis.

Authors:  Ghada S M Al-Bluwi; Asma H AlNababteh; Linda Östlundh; Saif Al-Shamsi; Rami H Al-Rifai
Journal:  Front Med (Lausanne)       Date:  2021-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.